Eloxx Pharmaceuticals Prices $66M Offering at 77% Premium, Uplists to Nasdaq
Summary
Eloxx Pharmaceuticals priced a $66.0 million public offering at $11.00 per share and $10.99 per pre-funded warrant, a substantial premium to its current OTC price of $6.20. This indicates strong investor confidence and demand for the company's stock. Concurrently, the company is uplisting to the Nasdaq Capital Market, with trading under the symbol ELOX set to begin on June 9, 2026. The significant capital infusion provides critical funding for the clinical-stage biopharmaceutical company, while the Nasdaq uplisting is a major step expected to enhance liquidity and attract institutional investors.
At the time of this announcement, ELOXD was trading at $6.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $260K. The 52-week trading range was $0.00 to $152.90. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.